Literature DB >> 20369832

Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.

Yukihiro Itoh1, Minoru Ishikawa, Mikihiko Naito, Yuichi Hashimoto.   

Abstract

Induction of selective degradation of target proteins by small molecules (protein knockdown) would be useful for biological research and treatment of various diseases. To achieve protein knockdown, we utilized the ubiquitin ligase activity of cellular inhibitor of apoptosis protein 1 (cIAP1), which is activated by methyl bestatin (MeBS, 2). We speculated that formation of an artificial (nonphysiological) complex of cIAP1 and a target protein would be induced by a hybrid molecule consisting of MeBS (2) linked to a ligand of the target protein, and this would lead to cIAP1-mediated ubiquitination and subsequent proteasomal degradation of the target protein. To verify this hypothesis, we focused on cellular retinoic acid-binding proteins (CRABP-I and -II) and designed hybrid molecules (compounds 4) consisting of MeBS (2) coupled via spacers of various lengths to all-trans retinoic acid (ATRA, 3), a ligand of CRABPs. Compounds 4 induced selective loss of CRABP-I and -II proteins in cells. We confirmed that 4b induced formation of a complex of cIAP1 and CRABP-II in vitro and induced proteasomal degradation of CRABP-II in cells. When neuroblastoma IMR-32 cells were treated with 4b, the level of CRABP-II was reduced and cell migration was inhibited, suggesting potential value of CRABP-II-targeting therapy for controlling tumor metastasis. Our results indicate that 4b possesses sufficient activity, permeability, and stability in cells to be employed in cellular assays. Hybrid molecules such as 4 should be useful not only as chemical tools for studying the biological/physiological functions of CRABPs but also as candidate therapeutic agents targeting CRABPs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20369832     DOI: 10.1021/ja100691p

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  87 in total

1.  Impact of linker length on the activity of PROTACs.

Authors:  Kedra Cyrus; Marie Wehenkel; Eun-Young Choi; Hyeong-Jun Han; Hyosung Lee; Hollie Swanson; Kyung-Bo Kim
Journal:  Mol Biosyst       Date:  2010-10-04

2.  Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo.

Authors:  Gopal Pathuri; Andria F Hedrick; Bryan C Disch; John T Doan; Michael A Ihnat; Vibhudutta Awasthi; Hariprasad Gali
Journal:  Bioconjug Chem       Date:  2011-12-20       Impact factor: 4.774

3.  In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs).

Authors:  Nobumichi Ohoka; Keiichiro Okuhira; Masahiro Ito; Katsunori Nagai; Norihito Shibata; Takayuki Hattori; Osamu Ujikawa; Kenichiro Shimokawa; Osamu Sano; Ryokichi Koyama; Hisashi Fujita; Mika Teratani; Hirokazu Matsumoto; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2017-02-02       Impact factor: 5.157

Review 4.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 5.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

6.  DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.

Authors:  Georg E Winter; Dennis L Buckley; Joshiawa Paulk; Justin M Roberts; Amanda Souza; Sirano Dhe-Paganon; James E Bradner
Journal:  Science       Date:  2015-05-21       Impact factor: 47.728

Review 7.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

8.  Two-headed PROTAC: an effective new tool for targeted protein degradation.

Authors:  Kedra Cyrus; Marie Wehenkel; Eun-Young Choi; Hollie Swanson; Kyung-Bo Kim
Journal:  Chembiochem       Date:  2010-07-26       Impact factor: 3.164

9.  Boc3Arg-Linked Ligands Induce Degradation by Localizing Target Proteins to the 20S Proteasome.

Authors:  Yuntao Shi; Marcus J C Long; Masha M Rosenberg; Shican Li; Aimee Kobjack; Philip Lessans; Rory T Coffey; Lizbeth Hedstrom
Journal:  ACS Chem Biol       Date:  2016-10-18       Impact factor: 5.100

10.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.

Authors:  Nobumichi Ohoka; Yoko Morita; Katsunori Nagai; Kenichiro Shimokawa; Osamu Ujikawa; Ikuo Fujimori; Masahiro Ito; Youji Hayase; Keiichiro Okuhira; Norihito Shibata; Takayuki Hattori; Tomoya Sameshima; Osamu Sano; Ryokichi Koyama; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2018-03-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.